|
|
Monitoring
individual response to brain-tumour chemotherapy: proton MR spectroscopy in a
patient with recurrent glioma after stereotactic radiotherapy
Lichy MP, Bachert P,
Henze M, Lichy CM, Debus J, Schlemmer HP
Department
of Radiology, German Cancer Research Centre, Im Neuenheimer Feld 280, 69120,
Heidelberg, Germany.
Since antineoplastic activity varies, sensitive methods for individual
assessment of efficacy are needed.
We demonstrate the clinical value of MR spectroscopy in monitoring chemotherapy
in a patient with recurrent glioma after stereotactic radiotherapy.
Diagnostic imaging before and after chemotherapy included contrast-enhanced MRI,
single-voxel proton MR spectroscopy ((1)H MRS), (1)H MR spectroscopic imaging
((1)H SI), and fluorodeoxyglucose (FDG) positron-emission tomography
(PET).
A significant decrease in choline signal intensity was observed 2 months after
chemotherapy indicating tumour chemosensitivity, in line with tumour shrinkage
on MRI and decreased uptake of FDG.
Assessment of early response by MRS may help to improve treatment protocols in
other patients.
PMID: 14685797 [PubMed - as supplied by publisher]
Source:
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=14685797&dopt=Abstract
|
